Literature DB >> 21813768

Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension.

Min Li1, Suzette R Riddle, Maria G Frid, Karim C El Kasmi, Timothy A McKinsey, Ronald J Sokol, Derek Strassheim, Barbara Meyrick, Michael E Yeager, Amanda R Flockton, B Alexandre McKeon, Douglas D Lemon, Todd R Horn, Adil Anwar, Carlos Barajas, Kurt R Stenmark.   

Abstract

Persistent accumulation of monocytes/macrophages in the pulmonary artery adventitial/perivascular areas of animals and humans with pulmonary hypertension has been documented. The cellular mechanisms contributing to chronic inflammatory responses remain unclear. We hypothesized that perivascular inflammation is perpetuated by activated adventitial fibroblasts, which, through sustained production of proinflammatory cytokines/chemokines and adhesion molecules, induce accumulation, retention, and activation of monocytes/macrophages. We further hypothesized that this proinflammatory phenotype is the result of the abnormal activity of histone-modifying enzymes, specifically, class I histone deacetylases (HDACs). Pulmonary adventitial fibroblasts from chronically hypoxic hypertensive calves (termed PH-Fibs) expressed a constitutive and persistent proinflammatory phenotype defined by high expression of IL-1β, IL-6, CCL2(MCP-1), CXCL12(SDF-1), CCL5(RANTES), CCR7, CXCR4, GM-CSF, CD40, CD40L, and VCAM-1. The proinflammatory phenotype of PH-Fibs was associated with epigenetic alterations as demonstrated by increased activity of HDACs and the findings that class I HDAC inhibitors markedly decreased cytokine/chemokine mRNA expression levels in these cells. PH-Fibs induced increased adhesion of THP-1 monocytes and produced soluble factors that induced increased migration of THP-1 and murine bone marrow-derived macrophages as well as activated monocytes/macrophages to express proinflammatory cytokines and profibrogenic mediators (TIMP1 and type I collagen) at the transcriptional level. Class I HDAC inhibitors markedly reduced the ability of PH-Fibs to induce monocyte migration and proinflammatory activation. The emergence of a distinct adventitial fibroblast population with an epigenetically altered proinflammatory phenotype capable of recruiting, retaining, and activating monocytes/macrophages characterizes pulmonary hypertension-associated vascular remodeling and thus could contribute significantly to chronic inflammatory processes in the pulmonary artery wall.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813768      PMCID: PMC3159707          DOI: 10.4049/jimmunol.1100479

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

1.  Aortic adventitial fibroblasts participate in angiotensin-induced vascular wall inflammation and remodeling.

Authors:  Brian C Tieu; Xiaoxi Ju; Chang Lee; Hong Sun; Wanda Lejeune; Adrian Recinos; Allan R Brasier; Ronald G Tilton
Journal:  J Vasc Res       Date:  2010-11-23       Impact factor: 1.934

Review 2.  Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation.

Authors:  R S Smith; T J Smith; T M Blieden; R P Phipps
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

Review 3.  Vascular smooth muscle progenitor cells: building and repairing blood vessels.

Authors:  Mark W Majesky; Xiu Rong Dong; Jenna N Regan; Virginia J Hoglund
Journal:  Circ Res       Date:  2011-02-04       Impact factor: 17.367

4.  HDAC inhibitors as anti-inflammatory agents.

Authors:  I M Adcock
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

Review 5.  Chemokines in vascular remodeling.

Authors:  Andreas Schober; Alma Zernecke
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

Review 6.  GM-CSF in inflammation and autoimmunity.

Authors:  John A Hamilton
Journal:  Trends Immunol       Date:  2002-08       Impact factor: 16.687

Review 7.  Fibroblasts as novel therapeutic targets in chronic inflammation.

Authors:  S J Flavell; T Z Hou; S Lax; A D Filer; M Salmon; C D Buckley
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

8.  Crosstalk between CXCR4/stromal derived factor-1 and VLA-4/VCAM-1 pathways regulates neutrophil retention in the bone marrow.

Authors:  Joseph M Petty; Christopher C Lenox; Daniel J Weiss; Matthew E Poynter; Benjamin T Suratt
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

Review 9.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

10.  Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis.

Authors:  John T Pesce; Thirumalai R Ramalingam; Margaret M Mentink-Kane; Mark S Wilson; Karim C El Kasmi; Amber M Smith; Robert W Thompson; Allen W Cheever; Peter J Murray; Thomas A Wynn
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

View more
  103 in total

1.  Perivascular Adventitial Fibroblast Specialization Accompanies T Cell Retention in the Inflamed Human Dermis.

Authors:  Alexander M S Barron; Julio C Mantero; Jonathan D Ho; Banafsheh Nazari; Katharine L Horback; Jag Bhawan; Robert Lafyatis; Christina Lam; Jeffrey L Browning
Journal:  J Immunol       Date:  2018-12-03       Impact factor: 5.422

Review 2.  Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia.

Authors:  Joseph M Collaco; Lewis H Romer; Bridget D Stuart; John D Coulson; Allen D Everett; Edward E Lawson; Joel I Brenner; Anna T Brown; Melanie K Nies; Priya Sekar; Lawrence M Nogee; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2012-07-06

3.  Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.

Authors:  Maria A Cavasin; Kim Demos-Davies; Todd R Horn; Lori A Walker; Douglas D Lemon; Nicholas Birdsey; Mary C M Weiser-Evans; Julie Harral; David C Irwin; Adil Anwar; Michael E Yeager; Min Li; Peter A Watson; Raphael A Nemenoff; Peter M Buttrick; Kurt R Stenmark; Timothy A McKinsey
Journal:  Circ Res       Date:  2012-01-26       Impact factor: 17.367

Review 4.  Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.

Authors:  Kurt R Stenmark; Rubin M Tuder; Karim C El Kasmi
Journal:  J Appl Physiol (1985)       Date:  2015-04-30

5.  Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats.

Authors:  Erquan Zhang; Junko Maruyama; Ayumu Yokochi; Yoshihide Mitani; Hirofumi Sawada; Masakatsu Nishikawa; Ning Ma; Kazuo Maruyama
Journal:  J Anesth       Date:  2015-05-01       Impact factor: 2.078

6.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series).

Authors:  Maria A Cavasin; Kurt R Stenmark; Timothy A McKinsey
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 9.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

10.  Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1.

Authors:  Min Li; Suzette Riddle; Hui Zhang; Angelo D'Alessandro; Amanda Flockton; Natalie J Serkova; Kirk C Hansen; Radu Moldovan; B Alexandre McKeon; Maria Frid; Sushil Kumar; Hong Li; Hongbing Liu; Angela Caánovas; Juan F Medrano; Milton G Thomas; Dijana Iloska; Lydie Plecitá-Hlavatá; Petr Ježek; Soni Pullamsetti; Mehdi A Fini; Karim C El Kasmi; QingHong Zhang; Kurt R Stenmark
Journal:  Circulation       Date:  2016-08-25       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.